Close this search box.
Close this search box.

Boyds collaborates with BioPharma Connections

Boyds partners with BioPharma Connections in the company’s latest move to continue its growth in the U.S.

BioPharma Connections is an independent, San Francisco-based biopharmaceutical consulting company that provides strategic business development support to life sciences companies, CROs, CDMOs, technical engineering/facilities service providers, and life sciences consulting firms. The company consults with its clients in the pharmaceutical, biotechnology, medical device, and diagnostic sectors to identify outsourcing, partnering, or investment needs from concept to commercialization.

Founded in 2005, Boyds has offices in the U.K. and opened its U.S. office in September 2021. Over the past two years, Boyds has established a team of regulatory and program management professionals based out of its King of Prussia, PA office. As a global drug development consultancy, Boyds already had a growing U.S. client base when the office opened and held a Queen’s Award for Enterprise in International Trade, which recognized the company’s export growth in the field of cell and gene therapies.

Commenting on the collaboration, Boyds’ President, Professor Alan Boyd, says: “With over 60% of our clients based in the U.S., this is a market of strategic importance to our growth. Since establishing our U.S. office just over two years ago, we have worked with many biotech and pharma companies looking to take their products forward for approval with regulators in the U.S., the U.K., and Europe via our U.K. and Dublin offices.”

“Working with the team at BioPharma Connections will help us expand our presence and profile in the U.S. while establishing new relationships with biotech and pharma companies seeking our support and expertise in cutting-edge development. With BioPharma Connections’ track record in offering quality connections, relationship management, and business development support, we look forward to realizing the opportunities our collaboration will bring.”

Teresa Johnk, President & CEO of BioPharma Connections, says, “we are delighted to work with Professor Boyd and his team. The company possesses the missing ingredient in the U.S. market, namely, the ability to facilitate the translation of cutting-edge science into medicinal products that benefit patients. We know how challenging this can be, which is why we have entered this partnership to connect U.S.-based companies to the unparalleled services of Boyds, who possess the ability to expedite development, add value to their client’s products, and reach those all-important key milestones. In addition, its recent accomplishments in the cell and gene therapies sectors make it an ideal fit for U.S.-based companies looking to make that all-important breakthrough in 2024 and beyond.”

BioPharma Connections will attend the 42nd J.P. Morgan Healthcare Conference in San Francisco this month.

Biopharma connections